Sourcing Bortenat 3.5mg Injection (Bortezomib): The Comprehensive B2B Procurement Guide for Global Wholesalers
For institutional buyers, hospital networks, and pharmaceutical distributors across major global healthcare hubs, navigating international regulations requires an experienced export partner. PRIMECARE IMPEX, a premier pharmaceutical exporter from India, bridges this gap by delivering wholesale lifelines efficiently to the United States, United Kingdom, Australia, and the Middle East.
🔬 Clinical Portfolio & Technical Specifications
Understanding the clinical profile of Bortenat 3.5mg helps procurement managers optimize storage, handling, and logistics.
1. Mechanism of Action (MOA)
Bortezomib is a first-in-class, highly specific proteasome inhibitor.
This targeted mechanism disrupts standard cell signaling pathways, leading directly to the programmed death (apoptosis) of cancerous cells while leaving healthy tissue less disrupted than traditional cytotoxic treatments.
2. Primary Therapeutic Indications
Bortenat 3.5mg is globally utilized in clinical protocols for:
Multiple Myeloma: Administered both as a frontline therapy and in relapsed/refractory settings, frequently in combination with dexamethasone or thalidomide.
Mantle Cell Lymphoma (MCL): Prescribed for adult patients who have received at least one prior therapy, helping restrict aggressive non-Hodgkin lymphoma progression.
💡 Key Advantages for Commercial Buyers
Sourcing Natco-manufactured Bortenat 3.5mg through an established Indian exporter offers clear operational advantages:
Cost Optimization: Substantially lowers institutional procurement budgets compared to western retail brand equivalents, allowing healthcare systems to maximize patient access.
Strict Quality Control: Manufactured under stringent GMP certified environments, ensuring every batch meets international safety, purity, and potency standards.
Flexible Logistics: Indian supply chains excel at managing specialized cargo, providing reliable transport configurations that maintain product integrity from the factory floor directly to global destination ports.
⚠️ Side Effects & Safety Profile
While highly effective, Bortezomib therapy requires close clinical observation due to potential systemic side effects:
Peripheral Neuropathy: Patients may experience tremors, numbness, burning sensations, or localized pain in the hands and feet.
Hematological Fluctuations: Can induce transient thrombocytopenia (low platelet counts), anemia, and neutropenia.
Regular complete blood counts (CBC) are recommended before each cycle. Gastrointestinal Distress: Nausea, vomiting, diarrhea, and decreased appetite are common but manageable with standard supportive care.
Systemic Fatigue: Dizziness and general lethargy may manifest during active treatment cycles.
📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India
PRIMECARE IMPEX is an established, high-volume pharmaceutical exporter, bulk supplier, and distributor specializing in oncology, life-saving, and critical-care therapeutics.
🌐 Website
PRESCRIPTION MEDICINE: YES
Bortenat 3.5mg (Bortezomib) is a highly regulated, hazardous chemotherapeutic intervention. It must be prepared, reconstituted, and administered strictly under the direct supervision of a qualified oncologist within a licensed clinical environment.
